Arcutis Appoints John W. Smither As Interim Chief Financial Officer, Effective August 31; Scott Burrows, Who Is Leaving The Company As Of Such Date To Pursue An External Opportunity
Portfolio Pulse from Happy Mohamed
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has appointed John W. Smither as interim Chief Financial Officer (CFO), effective August 31. He replaces Scott Burrows, who is leaving the company to pursue an external opportunity. Smither previously served as Arcutis' first CFO from 2019 to 2021 and led the company's successful IPO in 2020. He has also served as CFO for several other biopharmaceutical companies.
August 18, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
John W. Smither's appointment as interim CFO could bring stability to Arcutis Biotherapeutics, given his previous experience with the company and successful IPO leadership. However, Scott Burrows' departure might cause some uncertainty.
John W. Smither's return to Arcutis Biotherapeutics as interim CFO could bring stability due to his previous experience with the company and successful IPO leadership. However, the departure of Scott Burrows might introduce some uncertainty, which could potentially impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100